Navigation Links
Cephalon Quarterly Conference Call Invitation
Date:1/12/2009

Fourth Quarter & Full Year 2008 Earnings Conference Call

Thursday, February 12, 2009, 5:00 p.m. U.S. EST

FRAZER, Pa., Jan. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) has scheduled its regular quarterly earnings conference call covering fourth quarter and full year 2008 results for 5:00 p.m. EST on Thursday, February 12, 2009.

February 12, 2009 Schedule

4:10 p.m. EST Q4 & FY 2008 results will be distributed by PRNewswire

4:50 p.m. EST To participate in the conference call, dial 913-661-9178 and refer to Conference Code Number 9540364

5:00 p.m. EST Conference call begins promptly.

Simultaneous Webcast

Investors can listen to the call live by logging on to the company's website at www.cephalon.com and clicking on "Investor Information," then "Webcast." Please click on the link and follow the prompts for registration and access.

If you are unable to listen to the live broadcast, an audio or webcast replay of the call will be available approximately two hours after the event until Midnight EST, February 19, 2009. To listen to the audio replay, dial 1- 719-457-0820 and use the Conference Code Number 9540364.

Additional information presented on the conference call may be made available on the Investor Information page of the company's website.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference
2. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
3. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
4. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
5. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
6. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
7. Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
8. Cephalon Conference Call Invitation
9. Cephalon Reports Strong First Quarter Earnings
10. Cephalon Appoints Gerald J. Pappert as General Counsel
11. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... rise in the number of mobility devices around the ... suit the upsurge. Virtualization has become a growing trend ... The data traffic has increased by several folds with ... in larger and more complex networks. These global factors ... , The North American (NA) region is expected to ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... liver damage allegations continue to move forward in ... Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP ... 2014, U.S. District Judge Lawrence F. Stengel has ... Among other things, Judge Stengel found that the ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP notes ... metal ion levels to the failure of metal-on-metal hip ... issue of The Journal of Bone & Joint Surgery, ... unilateral Articular Surface Replacement prostheses at least twelve months ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4
... early childhood exposures to industrial chemicals in the environment ... neurodevelopmental disorders (NDDs)—autism,// attention deficit disorder (ADHD), and mental ... identify the individual chemicals that can cause injury to ... new review study, published in the print issue of ...
... treating common ear infections in children with ear tubes ... antibiotic ear drops over antibiotics swallowed// in pill or ... Center researcher reports. ,The latest study, involving ... and faster in treating middle ear infections in children ...
... publication in the Journal of Clinical Endocrinology and ... provided by The Hormone Foundation, the public education ... Lifestyle Accelerates Testosterone Decline ... but a new study confirms that many health ...
... certain vitamins, in order to reach out to the needful ... to be made a compulsion in bread would prevent neural ... prove to be harmful towards older people as folic acid ... and nervous problems in the long run. ,The pain ...
... as one of the toughest and most strenuous jobs. A ... the workload// and strain makes them sick. ,The ... nearly 19,000 nurses, which included registered nurses, licensed practical nurses ... that nurses face a variety of physical and emotional challenges ...
... will soon be reaching out to hundreds of people ... and support//. ,The US-based AIDS Healthcare Foundation (AHF) ... in Assam's main city of Guwahati, the eastern town ... ,India's National AIDS Control Organisation (NACO) and ...
Cached Medicine News:Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 2Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 3Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 4Health News:Antibiotic Ear Drops Favored Over Oral Antibiotics for Ear Infections 2Health News:Testosterone Decline in Men Linked to Lifestyle, Increases in Obese Girls 2Health News:Folic Acid Supplementation in Bread: Boon to Neonates and Curse to Pensioners 2Health News:US NGO to Counsel HIV/AIDS Patients in Assam 2
(Date:7/11/2014)... Research and Markets has announced ... X-ray Film Industry Report 2014" report to their ... Global And Chinese Medical X-Ray Film Industry Report ... current state of the Global medical X-ray film industry ... report provides a basic overview of the industry including ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Needles Market 2014-2018" report to their offering. ... hypodermic needle is a hollow needle commonly used with ... or to extract fluids from it. A hypodermic needle ... inject substances that cannot be ingested. Hypodermic needles are ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3
... Oct. 13, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in ... of a Multicenter Phase l/2 Trial" reporting Phase ... the treatment of advanced multiple myeloma (MM) patients, was ...
... PALO ALTO, Calif., Oct. 13, 2011 Telik, Inc. ... of a Phase 2b clinical trial to evaluate Telintra ... transfusion dependent, non-deletion (5q) myelodysplastic syndrome (MDS), who have ... Vidaza® or Dacogen®.  This patient population represents the majority ...
Cached Medicine Technology:Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 2Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 3Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 4Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome 2Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome 3
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Medicine Products: